Cite
MLA Citation
Ahmad Tarhini et al.. “Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.” Journal for immunotherapy of cancer, vol. 6, no. 1, 2018, p. . http://access.bl.uk/ark:/81055/vdc_100135572640.0x000005